Health Condition 1: Z511- Encounter for antineoplastic chemotherapy and immunotherapy
Conditions
Interventions
Intervention1: Not applicable: Not applicable
Control Intervention1: Not applicable: Not applicable
Sponsors
Tata Memorial Centre
St Jude Childrens Research Hospital
Eligibility
Inclusion criteria
Inclusion criteria: 1. All stakeholders (Healthcare Professionals involved in administration of Blinatumomab) 2. All the patients and their caregivers receiving Blinatumomab therapy
Exclusion criteria
Exclusion criteria: None
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1 The barriers & facilitators to blinatumomab implementation in LMIC, including pilot site infrastructure score, climate score & readiness score, & score of perceived intervention complexity 2 The implementation outcomes: feasibility, acceptability, appropriateness, fidelity 3 Relative importance and feasibility of discrete implementation strategies 4 Adequacy of training programs as defined by Training Material Feedback, Provider Specific Knowledge Assessment, and surrogate clinical measuresTimepoint: The interviews will be conducted after start of the treatment as the Blinatumomab is ongoing through the Blincyto Humanitarian Access Program, administered to the pediatric patients at baseline and during the therapy, at the end of therapy and 6 months survival data will be collected. Data from care providers will be collected once after initiation of the study at baseline and after providing training at 3 months and after 1 year via web-based systems designed and maintained by St. Jude. | — |
Secondary
| Measure | Time frame |
|---|---|
| NoneTimepoint: None | — |
Countries
India, Pakistan, Viet Nam
Contacts
Public ContactDr Gaurav Narula
Tata Memorial Hospital
Outcome results
None listed